Sequent Scientific Limited (BSE:512529) agreed to acquire Viyash Life Sciences Private Limited for INR 38 billion on September 26, 2024. The consideration consists of common equity of Sequent Scientific Limited at a ratio of 0.56 per common equity and warrants of Sequent Scientific Limited at a ratio of 0.56 per warrants of Viyash Life Sciences Private Limited.

For the period ended March 31, 2024 Viyash Life Sciences Private Limited reported total assets of INR 19 billion net assets of INR 18 billion and turnover of INR 1.83 billion.

The transaction is subject to approval from shareholders of Sequent Scientific Limited creditors of respective companies, statutory and regulatory authorities including stock exchanges, Securities and Exchange Board of India, Competition Commission of India and the National Company Law Tribunal. The transaction has been approved by the board of Sequent Scientific Limited. As of May 26, 2025, the transaction has been approved by NSE and BSE. As of January 21, 2025 Competition commission of India approved the transaction. As of May 26, 2025 Sequent Scientific Limited has received Observation Letters with ?No adverse observations? from BSE Limited and ?No objection? from the National Stock Exchange of India Limited.However, it is still subject to applicable regulatory and other approvals including the approval of the National Company Law Tribunal, Hyderabad. As of May 29, 2025 Sequent Scientific Limited has secured approvals from both the National Stock Exchange and the Bombay Stock Exchange for its proposed merger with Hyderabad-based Viyash Life Sciences. The company has now filed for clearance with the National Company Law Tribunal. As of November 20, 2025, the transaction has been approved by National Company Law Tribunal. As of November 26, 2025 Sequent Scientific Limited has fixed December 8, 2025, as the Record Date for determining the names of the shareholders of Viyash for the allotment of the Merger Consideration.

ICICI Securities Limited acted as fairness opinion provider for Sequent Scientific Limited. JM Financial Limited acted as financial advisor for Sequent Scientific Limited. KPMG acted as due diligence provider for Sequent Scientific Limited. Ernst & Young Private Limited acted as due diligence provider for Viyash Life Sciences Private Limited. AZB & Partners acted as legal advisor for Sequent Scientific Limited. Trilegal acted as legal advisor for Viyash Life Sciences Private Limited. Bain & Company India Pvt. Ltd. acted as due diligence provider for Sequent Scientific Limited.

Sequent Scientific Limited (BSE:512529) completed the acquisition of Viyash Life Sciences Private Limited on January 8, 2026.